Plasma metabolomic profiles could predict AMD progression

Article

Speaking at the American Academy of Ophthalmology 2021 annual meeting in New Orleans, Dr Ines Lains explained that the mechanisms of AMD progression currently remain poorly understood and the tools to predict and halt progression are limited.

Reviewed by Dr Ines Lains.

Plasma metabolomic profiles could predict AMD progression

Metabolomics, defined as the qualitative and quantitative analysis of metabolites <1-1.5 kilodaltons, may be able to contribute to the understanding age-related macular degeneration (AMD) progression and the identification of patients at higher risk for progression, according to Dr Ines Lains from Mass. Eye and Ear, Harvard Medical School, Harvard University, Boston.

Speaking at the American Academy of Ophthalmology 2021 annual meeting in New Orleans, Dr Lains explained that the mechanisms of AMD progression currently remain poorly understood and the tools to predict and halt progression are limited. Previous work, both by our group at MEE and others, have shown that plasma metabolomic profiles of patients AMD differ from controls. So far, no follow-up studies have been done. This study, for the first time, examined the association between metabolomics and AMD progression in a longitudinal study.

Longitudinal study of plasma metabolomics in AMD

Dr Ines Lains

Dr Ines Lains

Dr Lains and the team, under guidance of Drs Joan W. Miller and Deeba Husain, conducted a prospective longitudinal study to analyse the associations between baseline plasma metabolomic profiles and AMD progression at 3 years.

The main outcomes measures were AMD progression as documented in colour fundus photographs (retinal structure) and changes in time to dark adapt (retinal function).

Study results

A total of 153 eyes were included in the study: of these, 26 with progression of AMD at 3 years.

The analyses showed that 8 metabolites were associated with AMD progression based on colour fundus photographs, with an enrichment of the pentose and glucoronate interconversions pathway. Additionally, metabolites in the alanine, aspartate and glutamate pathway were associated with 3-year changes in dark adaptation.

“In this study we observed that baseline plasma metabolomic profiles are associated with progression of AMD at 3 years,” Dr Lains said. “In particular, the identified metabolites and metabolomic pathways are related to oxidative stress, suggesting that it may play a particularly important role in the progression of AMD both at structural and functional levels, as measured by dark adaptation.”

Dr Lains concluded that the findings contribute to our understanding of mechanisms of AMD progression as well as the development of future biomarkers and potential therapeutics for this blinding disease.

Ines Lains, MD, PhD
E: ines_Lains@meei.harvard.edu
Dr Lains reported no financial disclosures related to this content.

Related Content: Additional AAO content | Retina | Inflammation & Infection

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Related Content
© 2025 MJH Life Sciences

All rights reserved.